Icon

LEVOLET (nda021137)- (0.025MG,0.025MG,0.025MG,0.025MG,0.05MG,0.05MG,0.05MG,0.05MG,0.075MG,0.075MG,0.075MG,0.075MG,0.088MG,0.088MG,0.088MG,0.088MG,0.1MG,0.1MG,0.1MG,0.1MG,0.112MG,0.112MG,0.112MG,0.112MG,0.125MG,0.125MG,0.125MG,0.125MG,0.137MG,0.137MG,0.137MG,0.137MG,0.15MG,0.15MG,0.15MG,0.15MG,0.175MG,0.175MG,0.175MG,0.175MG,0.2MG,0.2MG,0.2MG,0.2MG,0.3MG,0.3MG,0.3MG,0.3MG)

LEVOTHYROXINE SODIUM GENUS LIFESCIENCES
0.025MG,0.025MG,0.025MG,0.025MG,0.05MG,0.05MG,0.05MG,0.05MG,0.075MG,0.075MG,0.075MG,0.075MG,0.088MG,0.088MG,0.088MG,0.088MG,0.1MG,0.1MG,0.1MG,0.1MG,0.112MG,0.112MG,0.112MG,0.112MG,0.125MG,0.125MG,0.125MG,0.125MG,0.137MG,0.137MG,0.137MG,0.137MG,0.15MG,0.15MG,0.15MG,0.15MG,0.175MG,0.175MG,0.175MG,0.175MG,0.2MG,0.2MG,0.2MG,0.2MG,0.3MG,0.3MG,0.3MG,0.3MG
No Yes
Expired Expired
None None
None No
LEVOLET is levothyroxine sodium (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
0 0 0
Total Other Developers None
Drugs with Suitability No
0.025MG ** ** - - -
0.05MG ** ** - - -
0.075MG ** ** - - -
0.088MG ** ** - - -
0.1MG ** ** - - -
0.112MG ** ** - - -
0.125MG ** ** - - -
0.137MG ** ** - - -
0.15MG ** ** - - -
0.175MG ** ** - - -
0.2MG ** ** - - -
0.3MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.